# Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy

> **NCT01225744** · PHASE2 · COMPLETED · sponsor: **The Christie NHS Foundation Trust** · enrollment: 47 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** UFT

## Key facts

- **NCT ID:** NCT01225744
- **Lead sponsor:** The Christie NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2014-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01225744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01225744, "Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01225744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*